{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:12:58Z","timestamp":1790665978589,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ahj.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T14:54:59Z","timestamp":1470927299000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction"],"prefix":"10.1016","volume":"181","author":[{"given":"Sofie Aagaard","family":"Rerup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia E.","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik M.","family":"Mogensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frants","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil L.","family":"Fosb\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ahj.2016.08.001_bb0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2016.08.001_bb0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwh237","article-title":"Familial hypercholesterolemia and coronary heart disease: a HuGE association review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.ahj.2016.08.001_bb0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.ahj.2016.08.001_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ahj.2016.08.001_bb0025","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ahj.2016.08.001_bb0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2011.03.027","article-title":"Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades","volume":"108","author":"Elis","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2016.08.001_bb0035","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"issue":"45","key":"10.1016\/j.ahj.2016.08.001_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.ahj.2016.08.001_bb0045","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.ahj.2016.08.001_bb0050","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jacc.2014.08.037","article-title":"Short- and long-term cause of death in patients treated with primary PCI for STEMI","volume":"64","author":"Pedersen","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2016.08.001_bb0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","article-title":"Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers","volume":"233","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ahj.2016.08.001_bb0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejim.2015.01.014","article-title":"Prevalence of DNA-confirmed familial hypercholesterolaemia in young patients with myocardial infarction","volume":"26","author":"Wald","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"36","key":"10.1016\/j.ahj.2016.08.001_bb0065","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/eurheartj\/ehv289","article-title":"Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes","volume":"36","author":"Nanchen","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2016.08.001_bb0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.atherosclerosis.2004.12.001","article-title":"The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population","volume":"180","author":"Damgaard","year":"2005","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.ahj.2016.08.001_bb0075","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ahj.2016.08.001_bb0080","first-page":"A4470","article-title":"Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids","volume":"59","author":"Siggaard-Andersen","year":"2012","journal-title":"Dan Med J"},{"issue":"9753","key":"10.1016\/j.ahj.2016.08.001_bb0085","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ahj.2016.08.001_bb0090","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ahj.2016.08.001_bb0095","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2016.08.001_bb0100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ahj.2015.11.005","article-title":"Untangling the paradox: obesity as prognostic marker in prevalent cardiovascular disease","volume":"172","author":"O'Brien","year":"2016","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316301545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316301545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:56:36Z","timestamp":1757570196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870316301545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":20,"alternative-id":["S0002870316301545"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2016.08.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}